Loteprednol etabonate is a site-specific, soft corticosteroid (C-20 ester corticosteroid) designed for topical ophthalmic use. It is a prodrug that undergoes rapid hydrolysis to an inactive metabolite, minimizing systemic absorption and side effects. It is highly effective in treating inflammatory and allergic conditions of the eye with a superior safety profile compared to older corticosteroids, particularly regarding intraocular pressure (IOP) elevation.
Adult: For inflammation: 1-2 drops in the affected eye(s) 4 times daily. For post-op inflammation: 1-2 drops in the operated eye(s) 4 times daily beginning 24 hours after surgery and continuing for 2 weeks. Dosing may be tapered.
Note: 1. Wash hands. 2. Tilt head back. 3. Gently pull lower eyelid down to form a pouch. 4. Instill prescribed number of drops without touching the dropper tip to eye or any surface. 5. Close eyes gently for 1-2 minutes. Apply gentle pressure to the nasolacrimal duct (inner corner of eye) for 1 minute to minimize systemic absorption. 6. Wait at least 5-10 minutes before instilling any other ophthalmic medication.
Loteprednol etabonate binds to glucocorticoid receptors in ocular tissues, forming a complex that translocates to the cell nucleus. This complex modulates gene transcription, leading to the synthesis of lipocortins. Lipocortins inhibit phospholipase A2, thereby preventing the release of arachidonic acid from membrane phospholipids. This blocks the subsequent production of key inflammatory mediators like prostaglandins and leukotrienes. It also inhibits the expression of cytokines, adhesion molecules, and other mediators of the inflammatory cascade.
Pregnancy: Category C: Animal studies have shown adverse effects. No adequate, well-controlled studies in pregnant women. Should be used only if the potential benefit justifies the potential risk to the fetus. Topical use results in minimal systemic levels.
Driving: May cause temporary blurred vision after instillation. Patients should not drive or operate machinery until vision clears.
| Other Ocular Corticosteroids | Additive risk of IOP elevation, cataract formation, and infection. | Major |
| Ocular NSAIDs (e.g., Ketorolac, Nepafenac) | May increase risk of corneal adverse events (ulceration, perforation) especially in complex ocular surgeries. Use combination with caution. | Moderate |
| Systemic Corticosteroids | Potential additive systemic corticosteroid effects. | Moderate |
| Immunosuppressants | Additive risk of ocular infections. | Moderate |